<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Oncohematology</journal-id><journal-title-group><journal-title xml:lang="en">Oncohematology</journal-title><trans-title-group xml:lang="ru"><trans-title>Онкогематология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1818-8346</issn><issn publication-format="electronic">2413-4023</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">318</article-id><article-id pub-id-type="doi">10.17650/1818-8346-2019-13-4-37-45</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>HEMATOLOGIC MALIGNANCIES: DIAGNOSIS, TREATMENT, SUPPORTIVE CARE</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ГЕМОБЛАСТОЗЫ: ДИАГНОСТИКА, ЛЕЧЕНИЕ, СОПРОВОДИТЕЛЬНАЯ ТЕРАПИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Blood coagulation in venous thrombosis, complicating treatment of children, adolescents and young adults with lymphomas</article-title><trans-title-group xml:lang="ru"><trans-title>Свертывание крови и антикоагулянтная терапия при венозных тромбозах, осложнивших лечение детей, подростков и молодых взрослых с лимфомами</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2738-429X</contrib-id><name-alternatives><name xml:lang="en"><surname>Dmitriev</surname><given-names>V. V.</given-names></name><name xml:lang="ru"><surname>Дмитриев</surname><given-names>В. В.</given-names></name></name-alternatives><address><country country="BY">Belarus</country></address><bio xml:lang="en"><p><italic>43 Frunzenskaya St.</italic><italic>, Borovlyani, Minsk region 223053</italic></p></bio><bio xml:lang="ru"><p>Вячеслав Васильевич Дмитриев </p><p><italic>223053 Минский р-н, д. Боровляны, ул. Фрунзенская, 43</italic></p></bio><email>dmitrievhaematol@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1559-8223</contrib-id><name-alternatives><name xml:lang="en"><surname>Fedorova</surname><given-names>A. S.</given-names></name><name xml:lang="ru"><surname>Федорова</surname><given-names>А. С.</given-names></name></name-alternatives><address><country country="BY">Belarus</country></address><bio xml:lang="en"><p><italic>43 Frunzenskaya St.</italic><italic>, Borovlyani, Minsk region 223053</italic></p></bio><bio xml:lang="ru"><p><italic>223053 Минский р-н, д. Боровляны, ул. Фрунзенская, 43</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8304-1005</contrib-id><name-alternatives><name xml:lang="en"><surname>Lipay</surname><given-names>N. V.</given-names></name><name xml:lang="ru"><surname>Липай</surname><given-names>Н. В.</given-names></name></name-alternatives><address><country country="BY">Belarus</country></address><bio xml:lang="en"><p><italic>43 Frunzenskaya St.</italic><italic>, Borovlyani, Minsk region 223053</italic></p></bio><bio xml:lang="ru"><p><italic>223053 Минский р-н, д. Боровляны, ул. Фрунзенская, 43</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6966-1892</contrib-id><name-alternatives><name xml:lang="en"><surname>Begun</surname><given-names>I. V.</given-names></name><name xml:lang="ru"><surname>Бегун</surname><given-names>И. В.</given-names></name></name-alternatives><address><country country="BY">Belarus</country></address><bio xml:lang="en"><p><italic>43 Frunzenskaya St.</italic><italic>, Borovlyani, Minsk region 223053</italic></p></bio><bio xml:lang="ru"><p><italic>223053 Минский р-н, д. Боровляны, ул. Фрунзенская, 43</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Dunaev</surname><given-names>I. A.</given-names></name><name xml:lang="ru"><surname>Дунаев</surname><given-names>И. А.</given-names></name></name-alternatives><address><country country="BY">Belarus</country></address><bio xml:lang="en"><p><italic>43 Frunzenskaya St.</italic><italic>, Borovlyani, Minsk region 223053</italic></p></bio><bio xml:lang="ru"><p><italic>223053 Минский р-н, д. Боровляны, ул. Фрунзенская, 43</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0233-7718</contrib-id><name-alternatives><name xml:lang="en"><surname>Dmitriev</surname><given-names>E. V.</given-names></name><name xml:lang="ru"><surname>Дмитриев</surname><given-names>Е. В.</given-names></name></name-alternatives><address><country country="BY">Belarus</country></address><bio xml:lang="en"><p><italic>43 Frunzenskaya St.</italic><italic>, Borovlyani, Minsk region 223053</italic></p></bio><bio xml:lang="ru"><p><italic>223053 Минский р-н, д. Боровляны, ул. Фрунзенская, 43</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Belarusian Research Center for Pediatric Oncology, Hematology and Immunology</institution></aff><aff><institution xml:lang="ru">ГУ «Республиканский научно-практический центр детской онкологии, гематологии и иммунологии»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2018-12-03" publication-format="electronic"><day>03</day><month>12</month><year>2018</year></pub-date><volume>13</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>37</fpage><lpage>45</lpage><history><date date-type="received" iso-8601-date="2019-01-02"><day>02</day><month>01</month><year>2019</year></date><date date-type="accepted" iso-8601-date="2019-01-02"><day>02</day><month>01</month><year>2019</year></date></history><permissions><copyright-year>2018</copyright-year><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://oncohematology.abvpress.ru/ongm/article/view/318">https://oncohematology.abvpress.ru/ongm/article/view/318</self-uri><abstract xml:lang="en"><p><bold><italic>Objective </italic></bold><italic>of the study was to compare blood clotting parameters in lymphoma patients with or without venous thrombosis (VT), as well as to analyze the duration and outcome of anticoagulant therapy in children, adolescents and young adults with lymphoma, whose program treatment was complicated by VT.<bold/></italic></p><p><bold><italic>Materials and methods . </italic></bold><italic>The analysis included 28 patients with lymphoma (Hodgkin lymphoma – 5, non-Hodgkin lymphoma – 23), aged from 2 to 25 years (median – 16.0 years), whose program treatment in 2005–2017 was complicated by VT. The case-control study was carried out to compare the parameters of blood coagulation. The control group consisted of 22 patients, aged from 2 to 20 years (median – 15.5 years) with the same diagnosis, age, therapy protocol and phase of treatment who had no thrombotic complications. The comparison group consisted of 35 healthy children aged from 3 to 18 years (median – 14.0 years).<bold/></italic></p><p><bold><italic>Results . </italic></bold><italic>There was no difference in majority of blood clotting parameters in lymphoma patients with or without VT. Hyperfibrinogenemia and an increased D-dimers level distinguished patients with lymphoma, regardless of the presence or absence of thrombosis, from healthy children of the same age (р</italic><italic> &lt;0.05). Anticoagulant therapy up to 3 months received 10 patients, for 4–6 months – 4, for 7–12 months – 12, up to 18 months – 2. One adult patient with a homozygous mutation 20210G&gt;A gene of the factor II takes warfarin continuously for a long time after relapse of VT. Complete recanalization of the thrombosed vessel occurred within the first 3 months in 9 patients, within 4–6 months – in 1, within 7–12 months ‒ in 4. Partial recanalization within 3–12 months was confirmed in 8 patients. Vein obliteration, mainly the internal jugular vein, as the outcome of VT occurred in 6 patients within 4–12 months.</italic></p><p><bold><italic>Conclusion . </italic></bold><italic>Detection of routine blood clotting parameters does not allow identifying patients with thrombosis among children, adolescents and young adults with lymphoma. Fibrinogen and D-dimers levels were significantly higher in lymphoma patients, than in healthy children. Anticoagulant therapy for 3–12 months led to the complete or partial recanalization of VT in 79 % of patients. To detect blood clotting parameters by thrombosis development, as well as to reveal and monitor transient and permanent risk factors are necessary to specify the cause of VT and to determine the appropriate anticoagulant therapy.<bold/></italic></p></abstract><trans-abstract xml:lang="ru"><p><bold><italic>Цель исследования </italic></bold><italic>– провести сравнительный анализ параметров свертывания крови у пациентов с венозным тромбозом (ВТ) и без него, оценить продолжительность и исход антикоагулянтной терапии при ВТ, осложнивших программное лечение детей, подростков и молодых взрослых с лимфомами.<bold/></italic></p><p><bold><italic>Материалы и методы . </italic></bold><italic>В анализ включены данные 28 пациентов (с лимфомой Ходжкина – 5, с неходжкинской лимфомой – 23) в возрасте от 2 до 25 лет (медиана 16 лет), программное лечение которых с 2005 по 2017 г. было осложнено ВТ. Cравнение параметров свертывания крови проводили исследованием случай–контроль. Контрольную группу составили 22 пациента в возрасте от 2 до 20 лет (медиана 15,5 года) с аналогичным диагнозом, полом, протоколом и этапом лечения, не имевших тромботических осложнений. Группу сравнения составили 35 здоровых детей в возрасте от 3 до 18 лет (медиана 14 лет).<bold/></italic></p><p><bold><italic>Результаты . </italic></bold><italic>Значения большинства показателей свертывания крови на момент выявления ВТ не отличались от таковых у пациентов контрольной группы. Повышенное содержание D-димеров отличало пациентов с лимфомой, независимо от наличия или отсутствия тромбоза, от здоровых детей такого же возраста (р &lt;0,05). Антикоагулянтную терапию с преимущественным использованием дальтепарина натрия продолжительностью до 3 мес получали 10 пациентов, в течение 4–6 мес – 4, 7–12 мес – 12, до 18 мес – 2. Без учета времени 1 взрослый с гомозиготной мутацией 20210G&gt;A гена фактора II после рецидива ВТ продолжает прием варфарина. Полная реканализация тромбированного сосуда наступила в течение первых 3 мес у 9 пациентов, за 4–6 мес – у 1, за 7–12 мес – у 4, частичная реканализация в течение 3–12 мес – у 8 пациентов. Облитерация вены, преимущественно внутренней яремной, как исход тромбоза наступила у 6 пациентов в течение 4–12 мес.<bold/></italic></p><p><bold><italic>Заключение . </italic></bold><italic>Определение рутинных показателей свертывания крови не позволяет выявить пациентов с тромбозом среди детей, подростков и молодых взрослых с лимфомой. У пациентов с лимфомой содержание D-димеров было значимо выше, чем у здоровых детей. Антикоагулянтная терапия привела к полной или частичной реканализации ВТ в течение 3–12 мес у 79 % пациентов. Регистрация показателей свертывания крови при развитии тромбоза, а также выявление и учет в динамике транзиторных и постоянно действующих факторов риска необходимы для уточнения причины ВТ и определения тактики антикоагулянтной терапии.<bold/></italic></p></trans-abstract><kwd-group xml:lang="en"><kwd>venous thrombosis</kwd><kwd>blood clotting</kwd><kwd>Hodgkin lymphoma</kwd><kwd>non-Hodgkin lymphoma</kwd><kwd>anticoagulant therapy</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>венозный тромбоз</kwd><kwd>свертывание крови</kwd><kwd>лимфома Ходжкина</kwd><kwd>неходжкинская лимфома</kwd><kwd>антикоагулянтная терапия</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1.	Khorana A.A. Venous thromboembolism and prognosis in cancer. Thromb Res 2010;125(6):490–3. DOI: 10.1016/j.thromres.2009.12.023. PMID: 20097409.</mixed-citation><mixed-citation xml:lang="ru">Khorana A.A. Venous thromboembolism and prognosis in cancer. Thromb Res 2010;125(6):490–3. DOI: 10.1016/j.thromres.2009.12.023. PMID: 20097409.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2.	Timp J.F., Braekkan S.K., Versteeg H.H., Cannegieter S.C. Epidemiology of cancerassociated venous thrombosis. Blood 2013;122(10):1712–23. DOI: 10.1182/blood-2013-04-460121. PMID: 23908465.</mixed-citation><mixed-citation xml:lang="ru">Timp J.F., Braekkan S.K., Versteeg H.H., Cannegieter S.C. Epidemiology of cancerassociated venous thrombosis. Blood 2013;122(10):1712–23. DOI: 10.1182/blood-2013-04-460121. PMID: 23908465.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3.	Athale U., Siciliano S., Thabane L. et al. Epidemiology and clinical risk factors predisposing to thromboembolism in children with cancer. Pediatr Blood Cancer 2008;51(6):792–7. DOI: 10.1002/pbc.21734. PMID: 18798556.</mixed-citation><mixed-citation xml:lang="ru">Athale U., Siciliano S., Thabane L. et al. Epidemiology and clinical risk factors predisposing to thromboembolism in children with cancer. Pediatr Blood Cancer 2008;51(6):792–7. DOI: 10.1002/pbc.21734. PMID: 18798556.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4.	Walker A., Grainge M., Card T. et al. Venous thromboembolism in children with cancer – a population-based cohort study. Thromb Res 2014;133(3):340–4. DOI: 10.1016/j.thromres.2013.12.021. PMID: 24388573.</mixed-citation><mixed-citation xml:lang="ru">Walker A., Grainge M., Card T. et al. Venous thromboembolism in children with cancer – a population-based cohort study. Thromb Res 2014;133(3):340–4. DOI: 10.1016/j.thromres.2013.12.021. PMID: 24388573.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5.	Kenet G., Lütkhoff L.K., Albisetti M. et al. Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and metaanalysis of observational studies. Circulation 2010;121(16):1838–47. DOI: 10.1161/CIRCULATIONAHA.109.913673. PMID: 20385928.</mixed-citation><mixed-citation xml:lang="ru">Kenet G., Lütkhoff L.K., Albisetti M. et al. Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and metaanalysis of observational studies. Circulation 2010;121(16):1838–47. DOI: 10.1161/CIRCULATIONAHA.109.913673. PMID: 20385928.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6.	Holmes M.V., Newcombe P., Hubacek J.A. et al. Effect modification by population dietary folateon the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomized trials. Lancet 2011;378(9791):584–94. DOI: 10.1016/S0140-6736(11)60872-6. PMID: 21803414.</mixed-citation><mixed-citation xml:lang="ru">Holmes M.V., Newcombe P., Hubacek J.A. et al. Effect modification by population dietary folateon the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomized trials. Lancet 2011;378(9791):584–94. DOI: 10.1016/S0140-6736(11)60872-6. PMID: 21803414.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7.	Lyman G.H., Khorana A.A., Kuderer N.M. et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013;31(17):2189–204. DOI: 10.1200/JCO.2013.49.1118. PMID: 23669224.</mixed-citation><mixed-citation xml:lang="ru">Lyman G.H., Khorana A.A., Kuderer N.M. et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013;31(17):2189–204. DOI: 10.1200/JCO.2013.49.1118. PMID: 23669224.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8.	Kearon С., Akl E., Ornelas J. et al. Antithrombotic therapy for VTE disease. CHEST guideline and expert panel report. Chest 2016;149(2):315–52. DOI: 10.1016/j.chest.2015.11.026. PMID: 26867832.</mixed-citation><mixed-citation xml:lang="ru">Kearon С., Akl E., Ornelas J. et al. Antithrombotic therapy for VTE disease. CHEST guideline and expert panel report. Chest 2016;149(2):315–52. DOI: 10.1016/j.chest.2015.11.026. PMID: 26867832.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9.	Monagle P., Chan A.K., Goldenberg N.A. et al. Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidencebased clinical practice guidelines. Chest 2012;141(2 Suppl):e737S–801S. DOI: 10.1378/chest.11–2308. PMID: 22315277.</mixed-citation><mixed-citation xml:lang="ru">Monagle P., Chan A.K., Goldenberg N.A. et al. Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidencebased clinical practice guidelines. Chest 2012;141(2 Suppl):e737S–801S. DOI: 10.1378/chest.11–2308. PMID: 22315277.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10.	Carrier M., Khorana A., Zwicker J. et al. Management of challenging cases of patients with cancerassociated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH. J Thromb Haemost 2013;11(9):1760–5. DOI: 10.1111/jth.12338. PMID: 23809334.</mixed-citation><mixed-citation xml:lang="ru">Carrier M., Khorana A., Zwicker J. et al. Management of challenging cases of patients with cancerassociated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH. J Thromb Haemost 2013;11(9):1760–5. DOI: 10.1111/jth.12338. PMID: 23809334.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11.	Cazals-Hatem D., Lepage E., Brice P. et al. Primary mediastinal large B-cell lymphoma: a clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA (“Groupe d’Etude des Lymphomas de l’Adulte”) study. Am J Surg Pathol 1996;20(7):877–88. PMID: 8669537.</mixed-citation><mixed-citation xml:lang="ru">Cazals-Hatem D., Lepage E., Brice P. et al. Primary mediastinal large B-cell lymphoma: a clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA (“Groupe d’Etude des Lymphomas de l’Adulte”) study. Am J Surg Pathol 1996;20(7):877–88. PMID: 8669537.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">12.	Kerlin B., Stephens J., Hogan M. et al. Development of a pediatric-specific clinical probability tool for diagnosis of venous thromboembolism: a feasibility study. Pediatr Res 2015;77(3):463–71. DOI: 10.1038/pr.2014.198. PMID: 25518012.</mixed-citation><mixed-citation xml:lang="ru">Kerlin B., Stephens J., Hogan M. et al. Development of a pediatric-specific clinical probability tool for diagnosis of venous thromboembolism: a feasibility study. Pediatr Res 2015;77(3):463–71. DOI: 10.1038/pr.2014.198. PMID: 25518012.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">13.	Andrew M., Vegh P., Johnston M. et al. Maturation of the hemostatic system during childhood. Blood 1992;80(8):1998–2005. PMID: 1391957.</mixed-citation><mixed-citation xml:lang="ru">Andrew M., Vegh P., Johnston M. et al. Maturation of the hemostatic system during childhood. Blood 1992;80(8):1998–2005. PMID: 1391957.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">14.	Toulon P., Berruyer M., BrionneFranqois M. et al. Age dependency for coagulation parameters in paediatric populations. Thromb Haemost 2016;116(1):9–17. DOI: 10.1160/TH15-12-0964. PMID: 26988943.</mixed-citation><mixed-citation xml:lang="ru">Toulon P., Berruyer M., BrionneFranqois M. et al. Age dependency for coagulation parameters in paediatric populations. Thromb Haemost 2016;116(1):9–17. DOI: 10.1160/TH15-12-0964. PMID: 26988943.</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">15.	Poort S.R., Rosendaal F.R., Reitsma P.H., Bertina R.M. A common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88(10):3698–703. PMID: 8916933.</mixed-citation><mixed-citation xml:lang="ru">Poort S.R., Rosendaal F.R., Reitsma P.H., Bertina R.M. A common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88(10):3698–703. PMID: 8916933.</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">16.	Nasiruddin, Zahur-ur-Rehman, Anwar M. et al. Frequency of factor V Leiden mutation. J Coll Physicians Surg Pak 2005;15(1):15–7. DOI: 01.2005/JCPSP.1517. PMID: 15670517.</mixed-citation><mixed-citation xml:lang="ru">Nasiruddin, Zahur-ur-Rehman, Anwar M. et al. Frequency of factor V Leiden mutation. J Coll Physicians Surg Pak 2005;15(1):15–7. DOI: 01.2005/JCPSP.1517. PMID: 15670517.</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">17.	Khorana A.A., Kuderer N.M., Culakova E. et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008;111(10):4902–7. DOI: 10.1182/blood-2007-10-116327. PMID: 18216292.</mixed-citation><mixed-citation xml:lang="ru">Khorana A.A., Kuderer N.M., Culakova E. et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008;111(10):4902–7. DOI: 10.1182/blood-2007-10-116327. PMID: 18216292.</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">18.	Bahl V., Hu H., Henke H.R. et al. A Validation study of a retrospective venous thromboembolism risk scoring method. Ann Surg 2010;251(2):344–50. DOI: 10.1097/SLA.0b013e3181b7fca6. PMID: 19779324.</mixed-citation><mixed-citation xml:lang="ru">Bahl V., Hu H., Henke H.R. et al. A Validation study of a retrospective venous thromboembolism risk scoring method. Ann Surg 2010;251(2):344–50. DOI: 10.1097/SLA.0b013e3181b7fca6. PMID: 19779324.</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">19.	Ay C., Dunkler D., Marosi C. et al. Prediction of venous thromboembolism in cancer patients. Blood 2010;116(24): 5377–82. DOI: 10.1182/blood-2010-02-270116. PMID: 20829374.</mixed-citation><mixed-citation xml:lang="ru">Ay C., Dunkler D., Marosi C. et al. Prediction of venous thromboembolism in cancer patients. Blood 2010;116(24): 5377–82. DOI: 10.1182/blood-2010-02-270116. PMID: 20829374.</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">20.	Pusterla S., Previtali S., Marziali S. et al. Antiphospholipid antibodies in lymphoma: prevalence and clinical significance. Hematol J 2004;5(4):341–6. DOI: 10.1038/sj.thj.6200377. PMID: 15297851.</mixed-citation><mixed-citation xml:lang="ru">Pusterla S., Previtali S., Marziali S. et al. Antiphospholipid antibodies in lymphoma: prevalence and clinical significance. Hematol J 2004;5(4):341–6. DOI: 10.1038/sj.thj.6200377. PMID: 15297851.</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">21.	Bairey O., Blickstein D., Monselise Y. et al. Antiphospholipid antibodies may be a new prognostic parameter in aggressive non-Hodgkin’s lymphoma. Eur J Haematol 2006;76(5):384–91. DOI: 10.1111/j.1600-0609.2005.00620.x. PMID: 16466368.</mixed-citation><mixed-citation xml:lang="ru">Bairey O., Blickstein D., Monselise Y. et al. Antiphospholipid antibodies may be a new prognostic parameter in aggressive non-Hodgkin’s lymphoma. Eur J Haematol 2006;76(5):384–91. DOI: 10.1111/j.1600-0609.2005.00620.x. PMID: 16466368.</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">22.	Genvresse I., Leftner D., Shelth-Schwalbe E., Buttgereit F. Prevalence and clinical significance of anticardiolipin and anti-β glycoprotein I antibodies in patients with non-Hodgkin’s lymphoma. Eur J Haematol 2002;68(2):84–90. PMID: 12038453.</mixed-citation><mixed-citation xml:lang="ru">Genvresse I., Leftner D., Shelth-Schwalbe E., Buttgereit F. Prevalence and clinical significance of anticardiolipin and anti-β glycoprotein I antibodies in patients with non-Hodgkin’s lymphoma. Eur J Haematol 2002;68(2):84–90. PMID: 12038453.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
